1. "2021"
Formats
  1. Journal Article (2507)
  2. Meeting Abstract (1731)
  3. Review (604)
  4. Editorial (358)
  5. Book Section (123)
  6. Correspondence (107)
  7. Guidelines (103)
  8. Research Letter (91)
  9. Miscellaneous (52)
  10. Conference Paper (34)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2534)
  2. Solid Tumor Oncology Division (1517)
  3. Sloan Kettering Institute Postdocs (1176)
  4. GSK Faculty (1088)
  5. Surgery (954)
  6. Survivorship Research (922)

More Groups

People
  1. Alexander Drilon (76)
  2. Miguel-Angel Perales (68)
  3. Sergio Giralt (66)
  4. Robert Motzer (65)
  5. Marc Ladanyi (62)
  6. Monica Morrow (57)

More People

Years
  1. 2021 (5712)
Publications
  1. Journal of Clinical Oncology (471)
  2. Blood (252)
  3. Annals of Oncology (148)
  4. Cancer Research (145)
  5. International Journal of Radiation Oncology, Biology, Physics (145)
  6. Journal of Thoracic Oncology (101)

More Publications

Publishers
  1. Elsevier Inc. (723)
  2. American Society of Clinical Oncology (522)
  3. Springer (381)
  4. Oxford University Press (360)
  5. Nature Publishing Group (344)
  6. American Association for Cancer Research (297)

More Publishers

Results (5712)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Improving referrals to survivorship: A patient-driven initiative
    Meeting Abstract

    Corcoran, S.; Licciardi, F.; Weber, E.; Duggan, E.; Woodside, A.; Correa, Z.; Lachaud-Richard, M.; Kassa, A.; Jakubowski, A. A.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy of avelumab + axitinib vs sunitinib by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101
    Meeting Abstract

    Haanen, J.; Larkin, J.; Choueiri, T.; Albiges, L.; Rini, B.; Atkins, M.; Schmidinger, M.; Penkov, K.; Thomaidou, D.; Wang, J.; more...
    Asia-Pacific Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Multi-omic characterization of lung tumors identify AKT and EZH2 as potential therapeutic targets in adenocarcinoma-to-squamous transdifferentiation
    Meeting Abstract

    Quintanal-Villalonga, Á.; Taniguchi, H.; Zhan, Y. A.; Hasan, M. M.; Chavan, S. S.; Uddin, F.; Allaj, V.; Manoj, P.; Shah, N.; Ciampricotti, M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • XPO1 inhibition strongly sensitizes to first-line and second-line therapy in small cell lung cancer
    Meeting Abstract

    Quintanal‐Villalonga, Á.; Taniguchi, H.; Hao, Y.; Chow, A.; Zhan, Y. A.; Uddin, F.; Allaj, V.; Manoj, P.; Shah, N.; Chan, J. M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Li, B. T.; Smit, E. F. F.; Goto, Y.; Nakagawa, K.; Udagawa, H.; Mazieres, J.; Nagasaka, M.; Bazhenova, L.; Saltos, A. N.; Felip, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
    Meeting Abstract

    Janjigian, Y. Y.; Ajani, J. A.; Moehler, M.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
    Meeting Abstract

    van Cutsem, E.; Di Bartolomeo, M.; Smyth, E.; Chau, I.; Park, H.; Siena, S.; Lonardi, S.; Wainberg, Z. A.; Ajani, J. A.; Chao, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004
    Meeting Abstract

    Swisher, E.; Miller, A.; Kohn, E.; Brady, M.; Radke, M.; Pennil, C.; Khasnavis, N.; Buscema, J.; Tew, W.; Muller, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • The role of oncology nurses in treatment-related adverse event management: An international online survey
    Meeting Abstract

    Fernández-Ortega, P.; Wittmer, B. A.; Pinheiro, N. A.; Belardi, P.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
    Meeting Abstract

    Weiss, J.; Yaeger, R. D.; Johnson, M. L.; Spira, A.; Klempner, S. J.; Barve, M. A.; Christensen, J. G.; Chi, A.; Der-Torossian, H.; Velastegui, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save